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Abstract
This chapter gives an overview about the most important malignant gastric tumours 
from the perspective of the pathologist. The first focus is the systematic classification 
of gastric carcinoma, neuroendocrine tumours, mesenchymal tumours and malig-
nant lymphoma with related histomorphology-based and molecular-based diagnosis 
criteria including differential diagnosis pathologists have to consider when dealing 
with gastric tumours. The second focus addresses the issues of personalized therapy 
options in gastric tumours pathologists have to bear in mind. Currently, some subtypes 
of gastric adenocarcinomas have been proposed with therapeutic implications like 
microsatellite-instable carcinoma and checkpoint-inhibition or Her2/neu positive ade-
nocarcinoma of intestinal-type and specific tyrosine-receptor blockade. Mesenchymal 
tumours are rare and can morphologically be quite variable. Mucosa-associated lym-
phoid tissue (MALT)-related marginal zone lymphoma is the most frequent gastric 
lymphoma but all other B-and T-cell lymphoma can occur in the stomach as well, and 
an exact subcharacterisation is very important due to different treatment decisions (e.g. 
eradication of helicobacter-pylori in MALT-lymphoma as first choice treatment vs. che-
motherapy in Burkitt-lymphoma). Pathologists have to consider a large spectrum of 
differential diagnosis and conflicting immunohistochemical and molecular results. It 
will become more and more important to find out therapeutically relevant tumour sub-
types and to use biomarkers to predict a successful individualized treatment.
Keywords: classification systems, diagnosis criteria, tumour subtyping, personalized 
treatment options
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Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
1. Introduction
The pathologist who deals with gastric tumours is responsible for the determination of the 
following factors:
• Dignity
• Main tumour differentiation (e.g. epithelial, mesenchymal, lymphatic)
• Treatment options
• Consider differential diagnosis (main differential diagnosis of gastric adenocarcinoma in-
clude neuroendocrine carcinoma, malignant lymphoma, metastasis of lobular breast carci-
noma, epithelioid angiosarcoma or malignant melanoma)
• Morphology-based subtyping of gastric carcinoma (according to WHO or Lauren)
• Grading
• Staging (according to TNM-classification)
• Surgery resection status (R0-R2)
• Treatment relevant biomarkers: Her2/neu in gastric adenocarcinoma or in gastrointestinal 
stromal tumour (GIST), mutational analysis of c-kit or PDGFR)
• Regression scores after neoadjuvant treatment
Adenocarcinoma (including different subtypes) is the most common malignant gastric 
tumours of epithelial origin. In Western countries, declining incidence of gastric carcinoma is 
found; nevertheless, it remains the second most common cause of cancer-related death in the 
world [3]. In Germany, we expect about 9200 men and 6400 women with a newly  diagnosed 
gastric carcinoma per year, and 70% of them will die carcinoma-related in the following 5 
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Figure 1. Pathogenesis of intestinal-type gastric adenocarcinoma.
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years. Particularly, if metastases/recurrences occur, the prognosis is still dismal with a median 
survival of 8 months (krebsdaten.de—Robert-Koch-Institut, Berlin 2015). Particularly, in 
Northern Europe and the United States, the distribution of carcinomas within the stomach 
changed in the past decades. The distal-located tumours (typically from the diffuse type of 
adenocarcinoma) are decreasing and the proximal tumours (typically from the intestinal type 
of adenocarcinoma) are increasing [1, 2].
From the pathophysiological point of view, main features of the intestinal type of gastric 
adenocarcinoma are (a) chronic inflammation of the mucosa (typically due to an infection of 
helicobacter pylori) with related mucosa damage and atrophy, (b) intraepithelial neoplasia 
and (c) fully invasive adenocarcinoma (Figure 1).
2. Classification of primary gastric carcinomas
In the past 90 years, there have been some different proposals for classification systems 
(Table 1). Especially in Western countries, the classification of Lauren (from 1965) and the cur-
rent World Health Organisation (WHO) (from 2010) are accepted and of practical importance.
In general, gastric adenocarcinomas are built of (a) cohesive tumour cells forming tubular or 
papillary structures or (b) poorly cohesive (and often but not always) single carcinoma cells. 
It is not uncommon to see different growth pattern in the same tumour (morphology-based 
tumour heterogeneity).
2.1. WHO classification
The current WHO classification system describes four main subtypes of gastric adenocarci-
noma and some rare entities [3].
2.1.1. Tubular adenocarcinoma
Cohesive tumour cells form slit-like, branching or someone dilated tubules or acinar struc-
tures. The individual carcinoma cells typically are columnar or cuboidal (Figure 2A).
2.1.2. Papillary adenocarcinoma
Papillary adenocarcinoma is usually a well-differentiated exophytic (finger-like) tumour. Fibro-
vascular tissue cores support the cohesive cylindrical or cuboidal tumour cells. Especially in 
superficial tumour biopsies, it is easy to miss an infiltrating growth pattern or desmoplastic 
stroma response (Figure 2B).
2.1.3. Mucinous adenocarcinoma
The main feature of this subtype is the dominance of extra-cellular mucinous pools—by defi-
nition, mucinous adenocarcinoma shows more than 50% extra-cellular mucin (Figure 2C). It 
is not uncommon to see some signet-ring cells scattered in the mucin.
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2.1.4. Signet-ring cell and other poorly cohesive adenocarcinoma
Non-cohesive, isolated single tumour cells or carcinoma cells arranged in only small aggre-
gates of few cells (Figure 2D).
Signet-ring cell carcinoma is composed of more than 50% signet-ring cells. The classic form 
of signet-ring cells is usually a single cell and has a central droplet of cytoplasmic mucin 
(optically clear in HE-staining). The atypical, hyperchromatic nucleus is eccentrically placed. 
Sometimes signet-ring cells can form lace-like glands.
WHO (2010) Lauren (1965) Goseki (1992) Ming (1992) Molecular (2014)
Papillary adenocarcinoma Intestinal type (Expanding type) Chromosomal 
instable, MSI*
Tubular adenocarcinoma Type 1 (type 2, 
type 3)
(Infiltrating type)
Mucinous adenocarcinoma
Signet-ring cell carcinoma Diffuse type type 4 Genomic stable
And other poorly cohesive 
carcinoma
Mixed carcinoma Indeterminate-type
Adenosquamous carcinoma
Squamous cell carcinoma
Hepatoid adenocarcinoma
Carcinoma with lymphoid 
stroma
EBV-related; MSI*
Choriocarcinoma
Carcinosarcoma
Parietal cell carcinoma
Malignant rhabdoid tumour
Mucoepidermoid carcinoma
Paneth cell carcinoma
Undifferentiated carcinoma
Mixed adeno-neuroendocrine 
carcinoma
Endodermal sinus tumour
Embryonal carcinoma
Pure gastric yolk sac tumour
Oncocytic adenocarcinoma
Notes: The correlation between the different classification systems is relative. The Ming classification cannot be assigned 
to the other classifications.
*MSI, microsatellite instable.
Table 1. Classification systems of adenocarcinoma.
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Other variants of poorly cohesive adenocarcinomas include (it is important to recognize that 
signet-ring cell carcinoma is just one subtype in the group of poorly cohesive adenocarci-
noma): single cells with deeply eosinophilic cytoplasm, bizarre nuclei, histiocytic-like or 
accompanied with prominent lymphatic stroma.
2.1.5. Mixed adenocarcinoma
As described above, gastric carcinoma is highly heterogeneous (from the morphological as well 
as molecular point of view). The ’mixed‘ subtype is composed of different cohesive or poorly 
cohesive tumour components of the main four subtypes described above (for example tubular 
and signet-ring cell components). It is recommended to describe any histological component.
2.1.6. Rare carcinoma variants (to see all: compare Table 1)
2.1.6.1. Adenocarcinoma with lymphoid stroma (lymphoepithelioma-like or medullary carcinoma)
Typically, poorly cohesive or vague tubular-forming tumour cells are associated with promi-
nent lymphoid stroma. Often small lymphocytes are scattered between tumour cells. Poorly 
2A
2C
2B
2D
Figure 2. Four main histological subtypes of gastric adenocarcinoma (WHO): (A) tubular adenocarcinoma, (B) papillary 
adenocarcinoma, (C) mucinous adenocarcinoma and (D) poorly differentiated non-cohesive adenocarcinoma.
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cohesive tumour cells can be misinterpreted as lymphatic blasts. Typically, this subtype is 
EBV-related and it is easy to detect EBV-RNA using in-situ-test like EBER. Furthermore, car-
cinoma cells are often immunohistochemically strong PD-L1 positive. Nevertheless, not all 
EBV-related adenocarcinomas show the typical medullary morphological features. Some car-
cinomas of this subtype are microsatellite-instable easy and cost-effective detectable using 
immunohistochemistry for MLH1 (MSH2, MLH6 and PMS2). The loss of one (or more) of 
these DNA-repair proteins in tumour cell nuclei is in keeping with microsatellite-instability.
2.1.6.2. Squamous cell carcinoma
A pure gastric squamous cell carcinoma is very rare and is suspicious for a metastasis. 
Sometimes a mixed adeno-squamous cell carcinoma can be seen.
2.2. Classification according to Lauren (established 1965)
2.2.1. Intestinal type
Cohesive tumour cells form tubular, papillary or solid structures. The tumour typically 
shows well-demarcated pushing borders and it is associated with chronic gastritis (usually 
w Hp-infection) including intestinal metaplasia and pre-cancerogenous epithelial lesions like 
flat intraepithelial neoplasia/dysplasia. Abundant intracytoplasmic mucin production is not 
a feature.
2.2.2. Diffuse type
Poorly or non-cohesive tumour cells include signet-ring cells. The tumour typically shows 
infiltrating margins. Usually intestinal metaplasia of the gastric mucosa or classic dysplasia is 
absent. Probably a signet-ring cell carcinoma in situ develops from the proliferative foveolar 
zone and directly invades into the lamina propria.
2.2.3. Indeterminate type
Mix of intestinal type and diffuse type tumour cells.
2.3. Goseki classification (established 1992)
According to the degree of tubular differentiation and the amount of intracellular mucin, this 
classification separates four subtypes.
1. Tubular differentiation, mainly (just a few tumour cells with intracellular mucin allowed)
2. Tubular differentiation accompanied by abundant intracellular mucin
3. Minor components of both: few tubular differentiations and few intracellular mucin
4. Abundant intracellular mucin and no/very few tubular differentiation
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2.4. Ming classification (established 1997)
According to the infiltration zone, tumours with expanding, pushing border and tumours 
with infiltrating margins have separated. Types and architecture of tumour cells are not 
included.
1. Expanding type
2. Infiltrating type
2.5. Molecular subtypes
Most recently, molecular-based classification systems were introduced. According to the 
results of the cancer genome atlas research network [4], four subtypes exist (including their 
distribution):
1. Chromosomal instable (49.8%)
2. Microsatellite instable (21.7%)
3. Genomic stable (19.6%)
4. Epstein-Barr virus related (8.9%)
According to the results of Cristescu et al., four subtypes exist associated with distinct clinical 
outcomes [5].
1. Microsatellite stable TP53 inactivated
2. Microsatellite stable TP53 activated
3. Microsatellite stable with epithelial-mesenchymal-transposition (EMT)
4. Microsatellite instable
2.5.1. Clinical significance
Her2/neu (ERBB2) is a well-known receptor tyrosine kinase in breast carcinoma and currently, 
it is the only established therapeutically important tyrosine kinase in gastric adenocarcinoma. 
According to the results of the TOGA study, patients show a statistically significant benefit 
when using the Her2-specific tyrosine kinase inhibitor trastuzumab in Her2/neu positive gas-
tric cancer. About 20% of gastric carcinomas are Her2/neu positive–most of them are located 
in the proximal part of the stomach and have an intestinal tumour differentiation. The role 
of the pathologists is the determination of the Her2-status on gastric carcinoma cells using 
immunohistochemistry or fluorescence-in situ (FISH). The criteria of Her2-positivity are dif-
ferent from that of breast carcinoma (compare Table 2).
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Gastric carcinomas are highly heterogeneous tumours and Her2/neu is usually not diffusely 
expressed in most of carcinoma cells (like it is commonly the case in breast carcinoma).
2.5.2. Molecular-based classification systems and prediction of treatment options
The molecular-based classification systems can be correlated to classical morphology-based 
divisions. The pathologist can use both to predict treatment options. The chromosomal insta-
ble/microsatellite stable subtype is more likely to belong to the intestinal type of adenocar-
cinoma or to the tubuloacinar-subtype and these tumours are more often correlated with a 
Her2/neu overexpression/amplification. The genomic stable/microsatellite stable with pithe-
lial-mesenchymal-transposition (EMT) subtype is typically related to the diffuse type of ade-
nocarcinoma or to the poorly cohesive adenocarcinoma including signet-ring cell carcinoma 
nearly never show Her2/neu positivity.
On the other hand, the microsatellite unstable or EBV-related subtypes can show different 
morphological patterns (sometimes associated with prominent lymphatic stroma) and are 
probably associated with better prognosis (Cristescu et al. described a better outcome in 
patients with microsatellite-instable tumours) and good treatment response to checkpoint-
inhibitors (currently subject of clinical trials). In view of the above, pathologists should con-
sider both traditional morphology-based and molecular-based classifications to find out the 
most reliable statement about prognosis and treatment options.
Cost-effective molecular-based classifications are possible using traditional morphology, 
immunohistochemistry (using antibodies against TP53, Her2/neu and MLH1) and in-situ 
technics (like EBER) [7, 8].
In surgical specimens, the determination of tumour stage is the most important prognostic 
factor in gastric carcinoma. In Western countries, the UICC-based TNM-classification system 
is well established (compare Table 3).
Gastric carcinoma Breast carcinoma
Cut-off Positive tumour cells
biopsy: ≥5 cells
resection: ≥10%
Positive tumour cells
≥10%
Pattern of expression (Baso-)lateral expression sufficient Circular expression required
Source: Modified according to Rüschoff et al. [6].
Table 2. Immunohistochemical Her2/neu criteria.
T Primary tumour
T1 Tumour invades lamina propria, muscularis mucosae or submucosa
T1a Tumour invades lamina propria or muscularis mucosa
T1b Tumour invades submucosa
T2 Tumour invades muscularis propria
T3 Tumour invades subserosa
T4 Tumour perforates serosa or invades adjacent structures
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The determination of tumour regression and estimation of the percentage of residual tumour 
after neoadjuvant chemo or radio-chemotherapy treatment is possible using standardized 
regression scores. Especially in Western countries, the regression score according to Becker et 
al. is well established (compare Table 4).
3. Pre-cancerogenous epithelial lesions
3.1. Adenoma
Gastric adenomas are polypoid and typically solitary lesions. They commonly arise in a back-
ground of chronic atrophic gastritis with accompanied intestinal metaplasia. By definition, the 
epithelia of adenomas are neoplastic (intraepithelial neoplasia/dysplasia). Most of them show 
an intestinal differentiation (including goblet cells, Paneth cells) and look like a colon adenoma. 
According to the classification of colon adenoma, they can be subdivided into tubular, villous 
T Primary tumour
T4a Tumour perforates serosa
T4b Tumour invades adjacent structures
N Regional lymph nodes
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in 1–2 regional lymph nodes
N2 Metastasis in 3–6 regional lymph nodes
N3 Metastasis in 7 or more regional lymph nodes
N3a Metastasis in 7–15 regional lymph nodes
N3b Metastasis in 16 or more regional lymph nodes
M Distant metastasis
M0 No distant metastasis
M1 Distant metastasis
Source: Modified according to Brierley et al [9].
Table 3. TNM classification.
1a No residual tumour (incl. treatment effect)
1b <10% residual tumour (incl. treatment effect)
2 10–50% residual tumour (incl. treatment effect)
3 >50% residual tumour (incl. treatment effect)
Sources: Becker et al [10].
Table 4. Regression score.
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or mixed adenomas and into low-grade or high-grade intraepithelial neoplasia. A minor group 
of gastric adenomas shows gastric gland differentiation like foveolar (so-called type II dyspla-
sia) or pyloric gland differentiation, a mixture of foveolar/intestinal like differentiation or (very 
rare) a predominant Paneth-cell differentiation.
3.2. Pyloric gland-adenoma
Pyloric gland-adenoma usually arises in women and has a background of atrophic autoimmune-
gastritis. This type of adenoma is polypoid and show closely packed pyloric gland-like tubuli. 
The epithelia are cuboidal with round nuclei and pale cytoplasm. Immunohistochemically 
pyloric gland-adenoma shows common gastric mucin (MUC 5A/C and MUC6).
3.2.1. Clinical significance
Adenomas must be removed with clear margins. Large adenomas (more than 2 cm) show a 
higher risk of malignancy.
3.3. Flat intraepithelial neoplasia
Especially in the stomach, intraepithelial neoplasia is flat and demonstrates endoscopically 
with only slight, uncharacteristic abnormalities. Frequently flat intraepithelial neoplasia 
arises in a background of chronic gastritis later in life (beyond the fifth decade). By conven-
tion, the intraepithelial neoplasia has to divide into either low grade or high grade.
Microscopically, the main characteristics of intraepithelial neoplasia consider cytology and 
architecture (like in adenoma):
Low-grade intraepithelial neoplasia preserves more or less the normal glandular differentia-
tion, the epithelia show enlarged hyperchromatic nuclei, the nucleoli are not prominent, and 
cell pleomorphism and cell stratification are limited.
High-grade intraepithelial neoplasia demonstrates with crowding of glands, including bud-
ding and branching of some glands. The nucleoli are prominent and often intense eosinophilic.
3.3.1. Clinical significance
Flat low-grade intraepithelial neoplasia: re-endoscopy to exclude concurrent carcinoma is 
suggested. The risk of carcinoma is low (about 25%). Re-endoscopy twice a year and annual 
after two negative endoscopies is suggested.
Flat high-grade intraepithelial neoplasia: the risk of accompanied carcinoma is high (about 
85%). An excision of the whole lesion/region is necessary [2, 11].
3.3.2. Vienna classification of gastrointestinal epithelial neoplasia
Geographic differences in interpretation of gastric epithelial tumours exist (generally between 
Western pathologists and Japanese pathologists). The Vienna classification of (pre-)cancerous 
lesions of the GI-tract tries to harmonize both interpretations (Table 5).
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4. Classification of neuroendocrine gastric tumours
According to WHO, tumours with neuroendocrine differentiation are separated into the 
following:
• well-differentiated neuroendocrine tumours (NETs) (grade 1 and grade 2)
• neuroendocrine carcinoma (NEC; subdivided into either small- and large-cell neuroendo-
crine carcinoma)
4.1. Neuroendocrine tumours (NETs)
NETs in total represent about 2% of all gastric malignancies.
Gastric neuroendocrine tumours (formerly ‘carcinoid tumours’) are mostly asymptomatic 
small ‘polyps’ on a background of hypergastrinemia-associated hyperplasia of endocrine 
cells in the gastric corpus of middle age adults (the ’classical’ type 1 gastric NET, compare 
Table 6). But rarely they also can be associated with syndromes or unrelated to hypergas-
trinemia —these rare manifestations are usually correlated to unusual locations (e.g. antrum, 
more aggressive behaviour) [2, 16].
According to clinico-pathophysiological characteristics, three types of gastric NETs have been 
proposed (Table 6). These types share the same histological pattern. The great majority are 
tumours of enterochromaffin-like (ECL) cells induced by hypergastrinemia and caused by 
chronic atrophic corpus gastritis due to autoimmune gastritis and consecutive hypochlorhy-
dria (type 1 NET) [3, 13, 17, 18].
Pathophysiologically, NETs start with ECL-cell hyperplasia (scattered or linear ECL-
hyperplasia), which may confluent to micronodules. More than five micronodules in a group 
are called adenomatoid ECL-hyperplasia. Enlargement of adenomatoid ECL-hyperplasia with 
Category 1 Negative for neoplasia/dysplasia
Category 2 Indefinite for neoplasia/dysplasia
Category 3 Non-invasive low-grade neoplasia (low-grade adenoma/dysplasia)
Category 4 Non-invasive high-grade neoplasia
4.1. High-grade adenoma/dysplasia
4.2. Non-invasive carcinoma (carcinom in situ)
4.3. Suspicion of invasive carcinoma
Category 5 Invasive neoplasia
5.1. Intramucosal carcinoma
5.2. Submucosal carcinoma or beyond
Source: From Schlemper et al. [12].
Table 5. Vienna classification of gastrointestinal epithelial neoplasia.
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invasion and accompanied stroma reaction, the term dysplastic ECL-hyperplasia can be used. If 
the dysplastic ECL-nodules exceed 0.5 mm or invade the submucosa, the correct term is NET [2].
NETs of all types are composed of uniform cuboidal cells with round nuclei with stippled 
(‘salt and pepper-like’) chromatin and eosinophilic, granular cytoplasm. Nuclear pleomor-
phism, nucleoli and mitosis are unusual/infrequent in typical NETs (unlike neuroendocrine 
carcinoma). Growth pattern of NETs can be quite different and even quite heterogeneous in 
the same tumour forming nests, trabecular, tubules, rosettes or solid structures of tumour 
cells. Immunohistochemically, gastric NETs are consistent chromogranin A positive and have 
by definition a low Ki67 (up to 2%) [19, 20].
4.2. Neuroendocrine carcinomas (NECs)
Gastric neuroendocrine carcinomas are very rare (separated into small-cell and large-cell 
NECs). These poorly differentiated tumours are highly proliferative active (>20 mitosis/10 
hpf or Ki67 >20%) and show an aggressive biological behaviour [3, 21].
Rare (atypical), NETs coexist with adenocarcinoma (‘adenocarcinoid)—so-called MANEC 
(mixed adeno-neuroendocrine carcinoma, according to WHO). MANECs have the similar 
prognosis to that of conventional adenocarcinoma [2].
Clinical significance:
• NET, type 1: usually endoscopic polypectomy
• NET, type 2: usually endoscopic polypectomy
• NET, type 3: Surgery (e.g. gastrectomy); polypectomy in small tumours [2]
Type 1 Type 2 Type 3 Indicators of behaviour
Background 
mucosa
Chronic atrophic 
corpus gastritis—
usually autoimmune
Hypertrophic with 
hyperplastic, intense 
eosinophilic parietal 
cells due to Zollinger-
Ellison syndrome—
usually MEN1
Normal (sporadic 
tumour)
Benign
<1 cm
mucosa or submucosa
no angioinvasion
ECL-hyperplasia Yes Yes No Low-grade malignant
beyond sumucosa 
angioinvasion
>2 cm
any endocrine 
functioning tumour
Ki67 > 2–20%
Size <1.5 cm multiple <1.5 cm multiple
> 1.5 cm in 20%
>1.5 cm, solitary rare
< 1.5 cm multiple
High-grade malignant
smaller or large cell
neuroendocrine 
carcinoma
Ki67 > 20%
Outcome Never fatal Rarely fatal 25% mortality
Sources: Modified from Abraham et al. [13]; Capella et al. [14], and Klöppel et al. [15].
Table 6. Typing of gastric neuroendocrine tumours.
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5. Classification of malignant non-epithelial gastric tumours
5.1. Mesenchymal tumours
5.1.1. Gastrointestinal stromal tumour (GIST)
GISTs represent the great majority of mesenchymal tumour of the stomach and arise from 
the GI-pacemaker cells of Cajal; nearly all of gastric GISTs have a close contact to the gastric 
muscle wall (muscularis propria). Due to the wide morphological differences in the appear-
ances of GIST: every mesenchymal tumour in the gastric wall is a GIST—until proven other-
wise (compare differential diagnosis in Section 5.1.2.).
GISTs are usually tumours of adults with equal sex distribution but can affect children as well. 
Most of GISTs are solitary (rarely multiple) sporadic tumours but in some predisposing con-
ditions like neurofibromatosis type 1, Carney-Stratakis syndrome (with paraganglioma and 
deficiency of succinate dehydrogenase) or associated with Carney triade (with extra-adrenal 
paraganglioma and pulmonary chondroma) tumours are more often multiple and show some 
other unusual features like epitheloid cell morphology or anatomical locations like oesopha-
gus (compare Table 7) [22–28].
GISTs vary in size from very small only incidentally identified to very large bulky tumours. 
Particularly, the large tumours demonstrate with cysts, haemorrhage or necrosis. The his-
tomorphology appearance is quite variable. Most GISTs show whorls, bundles or fascicle 
of monotonous spindle-cells with blunt-ended nuclei and eosinophilic cytoplasm (similar 
to tumours with muscle differentiation, compare Figure 3). Pleomorphism of tumour cells 
is not a typical feature (nevertheless some tumours can show striking pleomorphic nuclei). 
Sometimes paranuclear clear vacuoles or GISTs with small and intense eosinophilc homog-
enous filamentous material between tumour cells (skeinoid fibres; but usually seen in GIST of 
the small bowl) are seen. Some GISTs have an epitheloid cell appearance and these tumours 
are more often immunohistochemically CD117 negative. DOG1 (‘discovered on GIST’) is cur-
rently the protein with the highest sensitivity and specificity for GIST and is consistently posi-
tive in all epitheloid GISTs as well (compare Tables 7 and 8) [23, 29, 30].
The molecular basis for the CD117 protein-overexpression is an activating mutation of the 
c-kit gene (usually in the exons 9 or 11). A few tumours have mutations in platelet-derived 
growth factor receptor, alpha (PDGFRa), only.
Different mutations show different sensitivity to drug-related CD117 blockade (compare 
Table 9) [31]. Therefore, it is important to settle the exact underlying mutation.
Average age 60 40–50 <35 <25 50
Sex 1:1 1:1 w > m 1:1 1:1
Assoc. symptoms None Hyperpigmentation, 
Mastocytosis Urticaria
Extrarenal Paragan-
glioma Chondroma
Extrarenal 
Paragan-glioma
Neurofibroma 
Cafe-au-lait
Source: Modified according to Agarwal et al. [28].
Table 7. Clinico-pathological characteristics in GIST.
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It is important to realize that all GISTs have the potential to metastasize. But most gastric 
GISTs follow a benign biological behaviour. The most important tumour characteristics asso-
ciated with risk of progression are size, mitotic rate and anatomical location (but here we 
discuss gastric GIST, only) (compare Tables 9 and 10).
3A 3B 3C
Figure 3. Spindle cell GIST (c-kit and DOG1 immunohistochemistry): (A) spindle cell GIST (HE), (B) DOG1 and (C) 
CD117.
Antibody % of cases Remarks
CD117(=c-kit) 90 Membrane staining; sometimes paranuclear dot; can be negative mainly in 
epitheloid GIST
DOG-1 ≈100 Highest sensitivity and specificity
CD34 80 Low specificity
Vimentin ≈100 Very poor specificity; leiomyoma are negative for ‘Vimentin’
SMA +h-Caldesmon 30
Desmin <5 Most GIST are completely negative, sometimes patchy
S100 1–5 Focally
MelanA <1 Mainly in epitheloid GIST; DD: epitheloid PEComa
Table 8. Immunohistochemical markers in GIST.
Imatinib dosage in dependence of c-kit/PDGFRA-genotype
Genotype Imatinib dosage per day
c-kit Exon 11, 13, 17, wildtype 400 mg
c-kit Exon 9 800 mg
PDGFR-α-wild-type, Exon 12, 14 400 mg
PDGFR-α Exon 18 (D842V) mutation Imatinib resistant
Source: Modified from onkopedia; GIST.
Table 9. Imatinib dosage.
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5.1.2. Main differential diagnosis to GIST (including typical immunohistochemical/molecular 
findings)
• Leiomyoma/leiomyosarcoma—h-caldesmon, desmin
• Leiomyoma: usually small and related to muscularis mucosae. Very rare leiomyoma exist 
in the deeper gastric wall (usually located in the proximal part of the stomach). Diffuse 
positive for desmin, negative for dog1, CD117 (scattered mast cells between tumour cells 
are CD117 positive; mast-cell–rich leiomyoma can be challenging) and Vimentin
• Leiomyosarcoma: rare. Can look quite similar. Usually has much more cell pleomorphism
• Schwannoma—S100 and rim of lymphocytes in periphery of tumour
• Desmoid fibromatosis—ß-catenin nuclear expression
• Rhabdomyoma or rhabdomyosarcoma: Desmin, myogenin, MyoD1
• Haemangioma—ERG, CD31
• Calcifying fibrous tumour: paucillar, dense collagen, psammomatous calcification, patchy 
lymphocytes—factor XIIIa (in GI-tract usually adults, in soft tissue: usually children)
• Inflammatory fibroid polyp—CD34, PDGFRa
• Inflammatory myofibroblastic tumour—ALk1
• Solitary fibrous tumour (SFT)—STAT6
• Synovial sarcoma—TLE1
• Liposarcoma (well-/dedifferentiated or myxoid/roundcell)—mdm2 or FUS-CHOP-translocation
• Angiosarcoma (including: Kaposi-Sarcoma): ERG, CD31 (CAVE: macrophages)
• Clear cell sarcoma-like (malignant GI-neuroectodermal tumour): S100 (EWSR1 translocation)
• Glomustumour: SMA
Risk of progression Size (cm) Mitotic activity (per 50 hpf*)
None <2% <5
1.9% >2 to ≤5 <5
3.6% >5 to ≤10 ≤5
≤2 ≥5
10% >10 ≤5
16% >2 to ≤5 >5
55% >5 to ≤10 >5
86% >10 >5
*high power field
Source: Modified from: Miettinen et al. [32].
Table 10. Risk of progression of gastric GIST.
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• Gastroblastoma: benigne bi-phasic tumour in children. Epithelial component can be posi-
tive for CD117, mesenchymal component CD10 positive
• Granularcelltumour: S100
• Plexiform fibromyxoma: SMA, CD10 (very rare; multinodular, myxoid stroma, pauci-
cellular, no atypia, prominent capillary network, just few mitosis, typically in wall of 
stomach)
5.2. Malignant lymphoma
5.2.1. Marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT)
The great majority of gastric malignant lymphoma in Western countries belongs to the 
mucosa-associated lymphoid tissue (MALT) subtype. About 70–80% of MALT-lymphomas 
are associated with a chronic helicobacter pylori (Hp) infection. The Hp-infection is one of 
the main drivers of this type of lymphoma; eradication of Hp is the first choice of treatment 
and induces a regression of the MALT-lymphoma in about 75% of cases. Hp-negative MALT-
lymphoma can be associated with some other infections (like Hepatitis C) or are related 
to immunosuppression (due to AIDS or post-transplant) or some autoimmune diseases. 
Prognosis is mainly related to stage (Ann Arbor staging). Gastric MALT lymphoma occurs 
frequently multifocal. It is noteworthy that some gastric MALT lymphoma can affect other 
MALT-bearing organs like gut, salivary glands and bronchial [2, 33].
Endoscopically, (MALT)-lymphoma imitates carcinoma (including mucosa-ulceration) and is 
usually located in distal parts of the stomach. Sometimes non-characteristic gastritis-like or 
nodular appearance dominates.
Histologically, MALT-lymphoma shows the characteristics of other marginal zone lym-
phomas like dense infiltrations of small to intermediate-sized more or less monomorphic 
lymphoid cells with clear cytoplasm. Some tumours show a striking plasmacytoid-like dif-
ferentiation. Lympho-epithelial lesions (destruction of epithelial components of the mucosa) 
are highly characteristic for this type of lymphoma. Scattered blasts are typical [34, 35].
Immunohistochemically, MALT-lymphomas are positive for CD20 and half each for CD43. 
Negative for CD10, cyclin D1, CD5, CD23.
5.2.1.1. Clinical significance
Hp-eradication is the first choice of treatment (independent of Hp status at the surround-
ing mucosa). But tumours with nuclear BCL10 expression and positive translocation t (11;18) 
(q21;q21)) fail to response to Hp-eradication. This subtype is associated with a low risk of 
progression into an aggressive B-cell-lymphoma [36–38].
All other B- and T-cell-lymphomas and some other rare differential diagnosis can primary 
occur in the stomach, but are frequently an expression of a secondary infiltration (compare 
Sections 5.2.2–5.2.4) [39].
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5.2.2. Small cell B-cell-lymphoma
• Follicular lymphoma (grade1/2): CD10, BCL6, HGAL
• Mantle cell lymphoma: CD5, Cyclin D1 (due to translocation t(11;14), Sox11
• Lymphocytic lymphoma: CD23, CD5
5.2.3. High-grade B-cell-lymphoma
• Diffuse large B-cell-lymphoma: CD20, CD79a, Mum1, BCL2 positive. Some MALT-lym-
phomas show a transformation into an aggressive large B-cell-lymphoma.
• Burkitt-lymphoma: CD20, CD79a, BCL2 negative, CD10 positive. C-Myc translocation by 
FISH.
5.2.4. Others
• Primary solitary gastric plasmacytoma
• T-cell-lymphoma
• Langerhans cell histiocytosis, myeloid leukaemia
6. Metastasis
About 2.6% of all gastric tumours are metastases to the stomach.
Malignant melanoma is the most frequent reason for metastases followed by some carci-
noma: like lobular breast carcinoma (compare Figure 4) or colon, prostate, lung, pancreas, 
liver (mainly hepatocellular carcinoma) and very rare sarcoma (epithelioid angiosarcoma) 
[40–43].
The correct diagnosis can be quite challengingly—the following immunohistochemistry panel 
may help to find the correct answer:
Figure 4. Metastasis lobular breast carcinoma: (A) metastasis lobular breast carcinoma (HE), (B) estrogen-receptor and 
(C) GATA3.
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• AE1/AE3, GATA3, estrogen-receptor (progesterone -receptor, GCDFP): breast
• SOX10 (HMB45, MelanA, MITF): malignant melanoma
• SATB2, CDX2: colon
• Androgen-receptor (PSMA, NKX3.1, ERG): prostate
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